Indoco Remedies Limited

Indoco Remedies Limited (INDOCO) is a micro-cap Healthcare company valued at ₹2,267 crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move

Indoco Remedies Limited last traded at ₹238.3, modestly up 1.69% on the day.

Recent developments

2026-09-07: The USFDA inspected the company's Plant II (Sterile) facility in Goa and issued seven observations in Form 483, leading to a nearly 6% drop in shares.

Financial performance

The company's annual revenue rose 10.8% to ₹1,845 crore, but net profit turned into a loss of ₹99 crore, widening from a loss of ₹78 crore the previous year. In the latest quarter, revenue grew 6.2% to ₹468 crore, and net profit swung to a profit of ₹65 crore from a loss of ₹36 crore a year earlier.

Valuation multiples

The stock trades at 747.2 times earnings, a premium to the Healthcare median of 32.0, 2.50 times book value. It yields 0.1%.

Things to watch

The company reported a net loss of ₹99 crore for the latest fiscal year, with a net profit margin of -5.3%, down 0.7 percentage points from the prior year. The stock is 20.7% below its 52-week high, and the company's return on equity is -10.1%, indicating ongoing financial pressure.

Where it stands

Indoco Remedies ended the latest quarter with a net profit of ₹65 crore, reversing a loss from the same period a year earlier, but the company remains in a net loss for the full fiscal year. The most significant movement was the swing in net profit for the latest quarter, while the USFDA inspection introduced regulatory uncertainty.

Summarised by DocStoX's model on 2026-10-04 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.